598 results on '"Feliciani C."'
Search Results
2. Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study
- Author
-
Piraccini, B. M., Pampaloni, F., Cedirian, S., Quadrelli, F., Bruni, F., Rapparini, L., Caro, G., Acri, M. C., Ala, L., Rossi, A., Pellacani, G., Lacarrubba, F., Micali, G., Dall'Oglio, F., Vastarella, M., Cantelli, M., Nappa, P., Diluvio, L., Bianchi, L., Gnesotto, L., Sechi, A., Naldi, L., Tassone, F., Peris, Ketty, Caldarola, Giacomo, Pinto, Lorenzo Maria, Girolomoni, G., Marangoni, F., Bellinato, F., Gisondi, P., Scandagli, I., Prignano, F., Pimpinelli, N., Tomasini, C., Barruscotti, S., Desimoni, E., Simonetti, O., Ambrogio, F., Foti, C., Boccaletti, V., Fraghi, A., Marzano, A. V., Mattioli, M. A., Rocca, Lorenzo, Barbareschi, M., Ferrucci, S. M., Gallo, G., Ribero, S., Quaglino, P., Balestri, R., Ioris, T., Caposienacaro, R. D., Zalaudek, Iri, Vagnozzi, E., Fargnoli, Maria Concetta, Caponio, C., Rubegni, P., Cinotti, E., Trovato, E., Romanelli, Margherita, Dini, Veronica, Manzomargiotta, F., Feliciani, C., de FelicidelGiudice, M. B., Atzori, L., Sanna, S., Lembo, S., Raimondo, A., Magnano, M., Starace, M., Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), Pinto L. M., Rocca L., Zalaudek I., Fargnoli M. C., Romanelli M., Dini V., Piraccini, B. M., Pampaloni, F., Cedirian, S., Quadrelli, F., Bruni, F., Rapparini, L., Caro, G., Acri, M. C., Ala, L., Rossi, A., Pellacani, G., Lacarrubba, F., Micali, G., Dall'Oglio, F., Vastarella, M., Cantelli, M., Nappa, P., Diluvio, L., Bianchi, L., Gnesotto, L., Sechi, A., Naldi, L., Tassone, F., Peris, Ketty, Caldarola, Giacomo, Pinto, Lorenzo Maria, Girolomoni, G., Marangoni, F., Bellinato, F., Gisondi, P., Scandagli, I., Prignano, F., Pimpinelli, N., Tomasini, C., Barruscotti, S., Desimoni, E., Simonetti, O., Ambrogio, F., Foti, C., Boccaletti, V., Fraghi, A., Marzano, A. V., Mattioli, M. A., Rocca, Lorenzo, Barbareschi, M., Ferrucci, S. M., Gallo, G., Ribero, S., Quaglino, P., Balestri, R., Ioris, T., Caposienacaro, R. D., Zalaudek, Iri, Vagnozzi, E., Fargnoli, Maria Concetta, Caponio, C., Rubegni, P., Cinotti, E., Trovato, E., Romanelli, Margherita, Dini, Veronica, Manzomargiotta, F., Feliciani, C., de FelicidelGiudice, M. B., Atzori, L., Sanna, S., Lembo, S., Raimondo, A., Magnano, M., Starace, M., Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), Pinto L. M., Rocca L., Zalaudek I., Fargnoli M. C., Romanelli M., and Dini V. more...
- Abstract
Background: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata. Materials and Methods: We conducted a retrospective study involving 23 medical centres across Italy, enrolling patients affected by severe alopecia areata (SALT >50), for more than 6 months. Clinical and trichoscopic assessment was performed at each visit and impact on quality of life, anxiety and depression were evaluated using the Skindex-16 and the Hospital Anxiety and Depression Scale (HADS), respectively. Results: A total of 118 patients were enrolled, with a mean age of 39 years and a mean SALT >95. The mean value of the SALT score decreased from an average of 96.6 (±8.23 sd) to 48 (±35.2 sd) after 24 weeks of treatment and 42.3% of patients achieved a SALT 30, 31.3% a SALT 20 and 20.3% a SALT 10 by Week 24. Trichoscopic signs showed fewer yellow dots and black dots significantly earlier than hair regrowth. Adverse events during the treatment period (mild laboratory test abnormalities) were reported in 12.7% patients. No drop-out were registered. Conclusion: Data on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy. more...
- Published
- 2024
Catalog
3. Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patients
- Author
-
Piraccini, B. M., Rapparini, L., Quadrelli, F., Alessandrini, A., Bruni, F., Cedirian, S., Pampaloni, F., Marcelli, E., Bortolani, B., Giampieri, E., Gallo, G., Torrelli, F., Sciamarrelli, N., Quaglino, P., Tomasini, C., Barruscotti, S., Ambrogio, F., Foti, C., Picciallo, M., Caro, G., Rossi, A., Pellacani, G., Ala, L., Acri, M. C., Diluvio, L., Matteini, Elena, Bianchi, L., Argenziano, G., Babino, G., Fulgione, E., Gnesotto, L., Sechi, A., Naldi, L., Tassone, F., Peris, Ketty, Caldarola, Giacomo, Caposiena Caro, R. D., Bazzacco, G., Zalaudek, Iri, Vastarella, M., Cantelli, M., Patri, A., Dall'Oglio, F., Lacarrubba, F., Micali, G., Fraghi, A., Boccaletti, V., Marzano, A. V., Barbareschi, M., Silvio, M., Vagnozzi, E., Fargnoli, Maria Concetta, Caponio, C., Atzori, L., Sanna, S., Anedda, J., Feliciani, C., de Felici Del Giudice, M. B., Scandagli, I., Prignano, F., Rongioletti, F., Podo Brunetti, A., Bigotto, G. D., Offidani, A. M., Simonetti, O., Lembo, S., Raimondo, A., Balestri, R., Ioris, T., Gisondi, P., Bellinato, F., Trovato, E., Cinotti, E., Papini, M., Cicoletti, M., Corazza, M., Starace, M., Matteini E., Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), Zalaudek I., Fargnoli M. C., Piraccini, B. M., Rapparini, L., Quadrelli, F., Alessandrini, A., Bruni, F., Cedirian, S., Pampaloni, F., Marcelli, E., Bortolani, B., Giampieri, E., Gallo, G., Torrelli, F., Sciamarrelli, N., Quaglino, P., Tomasini, C., Barruscotti, S., Ambrogio, F., Foti, C., Picciallo, M., Caro, G., Rossi, A., Pellacani, G., Ala, L., Acri, M. C., Diluvio, L., Matteini, Elena, Bianchi, L., Argenziano, G., Babino, G., Fulgione, E., Gnesotto, L., Sechi, A., Naldi, L., Tassone, F., Peris, Ketty, Caldarola, Giacomo, Caposiena Caro, R. D., Bazzacco, G., Zalaudek, Iri, Vastarella, M., Cantelli, M., Patri, A., Dall'Oglio, F., Lacarrubba, F., Micali, G., Fraghi, A., Boccaletti, V., Marzano, A. V., Barbareschi, M., Silvio, M., Vagnozzi, E., Fargnoli, Maria Concetta, Caponio, C., Atzori, L., Sanna, S., Anedda, J., Feliciani, C., de Felici Del Giudice, M. B., Scandagli, I., Prignano, F., Rongioletti, F., Podo Brunetti, A., Bigotto, G. D., Offidani, A. M., Simonetti, O., Lembo, S., Raimondo, A., Balestri, R., Ioris, T., Gisondi, P., Bellinato, F., Trovato, E., Cinotti, E., Papini, M., Cicoletti, M., Corazza, M., Starace, M., Matteini E., Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), Zalaudek I., and Fargnoli M. C. more...
- Abstract
BACKGROUND: Alopecia areata (AA) is an organ-specific autoimmune disease that affects the hair follicles of the scalp and the rest of the body causing hair loss. Due to the unpredictable course of AA and the different degrees of severity of hair loss, only a few well-designed clinical studies with a low number of patients are available. Also, there is no specific cure, but topical and systemic anti-inflammatory and immune system suppressant drugs are used for treatment. The need to create a global registry of AA, comparable and reproducible in all countries, has recently emerged. An Italian multicentric electronic registry is proposed as a model to facilitate and guide the recording of epidemiological and clinical data and to monitor the introduction of new therapies in patients with AA. METHODS: The aim of this study was to evaluate the epidemiological data of patients with AA by collecting detailed information on the course of the disease, associated diseases, concomitant and previous events, and the clinical response to traditional treatments. Estimate the impact on the quality of life of patients. RESULTS: The creation of the National Register of AA has proven to be a valid tool for recording, with a standardized approach, epidemiological data, the trend of AA, response to therapies and quality of life. CONCLUSIONS: AA is confirmed as a difficult hair disease to manage due to its unpredictable course and, in most cases, its chronic-relapsing course, capable of having a significant impact on the quality of life of patients. more...
- Published
- 2024
4. Monitoraggio epidemiologico di un corso di e-learning per medici di medicina generale all’interno del Melanoma Multimedia Education Programme
- Author
-
Zamagni, F, Falcini, F, Magi, S, Bucchi, L, Crocetti, E, Mancini, S, Vattiato, R, Barruscotti, S, Borghi, A, Carugno, A, Falcinelli, S, Feliciani, C, Galdo, G, Lombardo, M, Melandri, D, Pizzichetta, M, Re, P, Recalcati, S, Ricci, F, Satta, R, Brusasco, M, Gandini, S, Stanganelli, I, Pizzichetta, MA, Satta, RR, Zamagni, F, Falcini, F, Magi, S, Bucchi, L, Crocetti, E, Mancini, S, Vattiato, R, Barruscotti, S, Borghi, A, Carugno, A, Falcinelli, S, Feliciani, C, Galdo, G, Lombardo, M, Melandri, D, Pizzichetta, M, Re, P, Recalcati, S, Ricci, F, Satta, R, Brusasco, M, Gandini, S, Stanganelli, I, Pizzichetta, MA, and Satta, RR more...
- Abstract
Introduzione. Nell’ambito del Piano Oncologico Nazionale 2023-2027 sull’importanza della formazione virtuale, multidisciplinare e interattiva, l’Intergruppo Melanoma Italiano (IMI) ha sviluppato MelaMEd (Melanoma Multimedia Education), un progetto nazionale per i medici di medicina generale (MMG) sulla prevenzione e diagnosi del melanoma cutaneo, basato su una piattaforma WEB e un corso online. MelaMEd consente ai partecipanti di (1) riconoscere lesioni cutanee che richiedono una valutazione dermatologica specialistica, (2) selezionare pazienti ad alto rischio di melanoma e (3) essere informati sul percorso diagnostico e terapeutico dei pazienti affetti da melanoma. Obiettivi. Il progetto ha l’obiettivo di dimostrare l’efficacia di MelaMEd nel migliorare l’abilità dei MMG nel riconoscere e gestire il melanoma. Inoltre, lo studio vuole identificare aree di miglioramento in cui intervenire per migliorare l’accuratezza diagnostica. Metodi. A giugno 2022, sono stati sviluppati e lanciati una piattaforma ed un corso online gratuiti. Prima di iniziare il corso, i partecipanti hanno compilato un questionario pre-formazione riguardante le conoscenze di base della malattia e il riconoscimento e la gestione delle lesioni sospette. Dopo il corso, i partecipanti hanno compilato nuovamente lo stesso questionario. Il corso è terminato a dicembre 2023. Presentiamo un'analisi descrittiva intermedia dei risultati (gennaio 2023-luglio 2023) ed un dato grezzo sulla adesione al completo percorso formativo, che consiste nel completamento di tutte e tre le fasi. Risultati. Al 31 luglio, avevano partecipato al progetto 5 centri per un totale di 1320 partecipanti. Di questi, 302 avevano compilato il questionario pre-formazione. Il 47% di loro aveva un'età <40 anni. Gli intervistati erano equamente divisi tra medici di base (47%) e medici in formazione (48%). Tra le domande teoriche, sono risultate ben note le regole dell’“ABCDE” e del “brutto anatroccolo” (rispettivamente 96% e 91% d more...
- Published
- 2024
5. Social groups in pedestrian crowds as physical and cognitive entities: Extent of modeling and motion prediction
- Author
-
Feliciani, C, Jia, X, Murakami, H, Ohtsuka, K, Vizzari, G, Nishinari, K, Feliciani C., Jia X., Murakami H., Ohtsuka K., Vizzari G., Nishinari K., Feliciani, C, Jia, X, Murakami, H, Ohtsuka, K, Vizzari, G, Nishinari, K, Feliciani C., Jia X., Murakami H., Ohtsuka K., Vizzari G., and Nishinari K. more...
- Abstract
Most pedestrian crowds are composed of social groups that are typically formed by dyads (two members), triads (three members), or larger groups. Depending on the context, social groups may make up half or even more of the membership of the crowd. Therefore, understanding their motion is crucial for predicting crowd dynamics. The presence of social groups modifies crowd behavior. When the proportion and size of groups are known, crowd motion (e.g., the “flow” of passengers collectively moving inside a train station) could become predictable. However, a bidirectional flow experiment performed in 2010 revealed that the presence of groups could lead to partially surprising results because crowds composed of small social groups moved more smoothly than those composed of individuals (singletons). Results were partially disregarded because of statistical insignificance. A subsequent experiment in 2015 with latest tracking techniques resulted in similar results and investigated the cause of the superior flow in the presence of groups. The results revealed that when groups arrange themselves in certain shapes, their partially “obstructing” nature (in a counterintuitive manner) facilitates lane formation, which benefits overall crowd motion. Because the arrangement of a dyad, i.e., whether both members walk next to each other or in a front–back alignment, is partially linked to the coordination (or the lack thereof) between both members, predicting such a mechanism is difficult. Simulation results from a commercial software program confirmed that predicting the dynamics of social groups is not trivial; however, at the macroscopic scale, some general trends are depicted at least from a qualitative perspective. This study revealed that, whenever possible, several crowd composition patterns should be considered when planning crowd events or drafting safety guidelines for pedestrian facilities. Depending on the context, crowds composed of individuals may move smoother than social more...
- Published
- 2023
6. A Residual Pigmentary Lesion After Melanoma Surgery
- Author
-
Rovesti, M., primary, Feliciani, C., additional, Zucchi, A., additional, Lotti, T., additional, and Satolli, F., additional
- Published
- 2020
- Full Text
- View/download PDF
7. Mitochondrial DNA haplogroups may influence Fabry disease phenotype
- Author
-
Simoncini, C., Chico, L., Concolino, D., Sestito, S., Fancellu, L., Boadu, W., Sechi, G.P., Feliciani, C., Gnarra, M., Zampetti, A., Salviati, A., Scarpelli, M., Orsucci, D., Bonuccelli, U., Siciliano, G., and Mancuso, M. more...
- Published
- 2016
- Full Text
- View/download PDF
8. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy
- Author
-
Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., Peris, K., Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., and Peris, K. more...
- Published
- 2022
9. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis
- Author
-
Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Gurioli, C., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, Ketty, Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Esposito, M., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, Andrea, Tramontana, M., Hansel, K., Buligan, C., Caroppo, F., Bello, G. D., Dastoli, S., Di Brizzi, E. V., Del Giudice, M. B. D. F., Diluvio, L., Fargnoli, Maria Concetta, Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Motolese, A., Neri, I., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), Fargnoli M. C., Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Gurioli, C., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, Ketty, Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Esposito, M., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, Andrea, Tramontana, M., Hansel, K., Buligan, C., Caroppo, F., Bello, G. D., Dastoli, S., Di Brizzi, E. V., Del Giudice, M. B. D. F., Diluvio, L., Fargnoli, Maria Concetta, Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Motolese, A., Neri, I., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), and Fargnoli M. C. more...
- Abstract
na
- Published
- 2023
10. Not a simple plantar wart: a case of tungiasis
- Author
-
Peccerillo, F., Zambito Spadaro, F., Fabrizi, G., Feliciani, C., Pagliarello, C., and Stanganelli, I.
- Published
- 2018
- Full Text
- View/download PDF
11. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience
- Author
-
Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, K., Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Fargnoli, M. C., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, A., Tramontana, M., Hansel, K., Bini, V., Buligan, C., Caroppo, F., Dal Bello, G., Dastoli, S., Di Brizzi, E. V., De Felici Del Giudice, M. B., Diluvio, L., Esposito, M., Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Peccerillo, F., Pluchino, F., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Stingeni, L, Bianchi, L, Antonelli, E, Caroppo, E S, Ferrucci, S M, Ortoncelli, M, Fabbrocini, G, Nettis, E, Schena, D, Napolitano, M, Gola, M, Bonzano, L, Rossi, M, Belloni Fortina, A, Balato, A, Peris, K, Foti, C, Guarneri, F, Romanelli, M, Patruno, C, Savoia, P, Fargnoli, M C, Russo, F, Errichetti, E, Bianchelli, T, Pellacani, G, Feliciani, C, Offidani, A, Corazza, M, Micali, G, Milanesi, N, Malara, G, Chiricozzi, A, Tramontana, M, and Hansel, K more...
- Subjects
SARS-CoV-2 ,Pruritus ,Eczema ,COVID-19 ,Dermatitis ,Dermatology ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Atopic ,Antibodies ,COVID-19 Drug Treatment ,Dermatitis, Atopic ,Treatment Outcome ,Settore MED/35 ,Infectious Diseases ,Double-Blind Method ,Monoclonal ,Humans ,Prospective Studies ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,Pandemics ,Humanized - Abstract
Background Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from >= 12 to more...
- Published
- 2022
12. Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt)
- Author
-
Papini, M, Russo, A, Simonetti, O, Borghi, A, Corazza, M, Piaserico, S, Feliciani, C, Calzavara-Pinton, P, Amendolagine, G, Arisi, M, Babino, G, Bardazzi, F, Belloni Fortina, A, Cac-Cavale, S, Campanati, A, Campione, E, Caposiena, C, Carugno, A, Coati, I, Cinotti, E, D'Antuono, A, Dattola, A, Dika, E, Fai, D, Fusano, M, Galluzzo, M, Ganzetti, G, Gisondi, P, Hansel, K, Lora, V, Maione, V, Mandel, V, Menni, S, Negosanti, M, Neri, I, Offidani, A, Parodi, A, Patrizi, A, Peserico, A, Rossi, M, Rivetti, N, Saccani, E, Stan, T, Stingeni, L, Talamonti, M, Vascellaro, A, Vezzoli, P, Virgili, A, Zanca, A, Papini M., Russo A., Simonetti O., Borghi A., Corazza M., Piaserico S., Feliciani C., Calzavara-Pinton P., Amendolagine G., Arisi M., Babino G., Bardazzi F., Belloni Fortina A., Cac-Cavale S., Campanati A., Campione E., Caposiena C. D., Carugno A., Coati I., Cinotti E., D'Antuono A., Dattola A., Dika E., Fai D., Fusano M., Galluzzo M., Ganzetti G., Gisondi P., Hansel K., Lora V., Maione V., Mandel V. D., Menni S., Negosanti M., Neri I., Offidani A., Parodi A., Patrizi A., Peserico A., Rossi M., Rivetti N., Saccani E., Stan T. R., Stingeni L., Talamonti M., Vascellaro A., Vezzoli P., Virgili A., Zanca A., Papini, M, Russo, A, Simonetti, O, Borghi, A, Corazza, M, Piaserico, S, Feliciani, C, Calzavara-Pinton, P, Amendolagine, G, Arisi, M, Babino, G, Bardazzi, F, Belloni Fortina, A, Cac-Cavale, S, Campanati, A, Campione, E, Caposiena, C, Carugno, A, Coati, I, Cinotti, E, D'Antuono, A, Dattola, A, Dika, E, Fai, D, Fusano, M, Galluzzo, M, Ganzetti, G, Gisondi, P, Hansel, K, Lora, V, Maione, V, Mandel, V, Menni, S, Negosanti, M, Neri, I, Offidani, A, Parodi, A, Patrizi, A, Peserico, A, Rossi, M, Rivetti, N, Saccani, E, Stan, T, Stingeni, L, Talamonti, M, Vascellaro, A, Vezzoli, P, Virgili, A, Zanca, A, Papini M., Russo A., Simonetti O., Borghi A., Corazza M., Piaserico S., Feliciani C., Calzavara-Pinton P., Amendolagine G., Arisi M., Babino G., Bardazzi F., Belloni Fortina A., Cac-Cavale S., Campanati A., Campione E., Caposiena C. D., Carugno A., Coati I., Cinotti E., D'Antuono A., Dattola A., Dika E., Fai D., Fusano M., Galluzzo M., Ganzetti G., Gisondi P., Hansel K., Lora V., Maione V., Mandel V. D., Menni S., Negosanti M., Neri I., Offidani A., Parodi A., Patrizi A., Peserico A., Rossi M., Rivetti N., Saccani E., Stan T. R., Stingeni L., Talamonti M., Vascellaro A., Vezzoli P., Virgili A., and Zanca A. more...
- Abstract
Lichen sclerosus (LS) is a disabling chronic inflammatory disease of skin and genital mucous membrane causing itch, pain, dysuria and restriction of micturition, and significant sexual dysfunction and dyspareunia both in women and men. If left untreated, LS is associated with a high degree of sclerosis and scarring, as well as with an elevated risk of cancer in the genital area. Although a central role of autoimmunity is suggested, the pathogenesis of LS is still not clearly understood and the disease remains difficult to treat. The goals of treatment of LS are to alleviate symptoms and discomfort, prevent anatomical changes and prevent malignant transformation. this guideline has been developed by an Italian group of experts. It summarizes evidence-based and expert- based recommendations. The highest level of evidence favors the use of topical high potency corticosteroids; second- and third-line treatments include topical calcineurin inhibitors and topical retinoids, respectively. Surgical treatment has become the treatment of choice in male genital LS with persistent phimosis not responsive to medical treatment. The aim of this paper is to offer evidence-based and easily applicable recommendations for the management of lS. more...
- Published
- 2021
13. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry
- Author
-
Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., Piras V., Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., and Piras V. more...
- Abstract
Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients. more...
- Published
- 2021
14. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study
- Author
-
Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., and Peris, K. more...
- Abstract
Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen ‘cytokine storm’ of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death. more...
- Published
- 2021
15. Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study
- Author
-
Bardazzi, F., primary, Filippi, F., additional, Chessa, M.A., additional, Iommi, M., additional, Loi, C., additional, Campanati, A., additional, Rizzetto, G., additional, Tagliati, C., additional, Atzori, L., additional, Muratori, S., additional, Genovese, G., additional, Gisondi, P., additional, Schena, D., additional, Balestri, R., additional, Rech, G., additional, Feliciani, C., additional, Lasagni, C., additional, Bigi, L., additional, De Simone, C., additional, Di Zenzo, G., additional, Moro, F., additional, Borghi, A., additional, Di Lernia, V., additional, D'Arrigo, G., additional, Tripepi, G., additional, Gori, M., additional, and Pitino, A., additional more...
- Published
- 2022
- Full Text
- View/download PDF
16. Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt)
- Author
-
Papini, M., Russo, A., Simonetti, O., Borghi, A., Corazza, M., Piaserico, S., Feliciani, C., Calzavara-Pinton, P., Amendolagine, G., Arisi, M., Babino, G., Bardazzi, F., Belloni Fortina, A., Cac-Cavale, S., Campanati, A., Campione, E., Caposiena, C. D., Carugno, A., Coati, I., Cinotti, E., D'Antuono, A., Dattola, A., Dika, E., Fai, D., Fusano, M., Galluzzo, M., Ganzetti, G., Gisondi, P., Hansel, K., Lora, V., Maione, V., Mandel, V. D., Menni, S., Negosanti, M., Neri, I., Offidani, A., Parodi, A., Patrizi, A., Peserico, A., Rossi, M., Rivetti, N., Saccani, E., Stan, T. R., Stingeni, L., Talamonti, M., Vascellaro, A., Vezzoli, P., Virgili, A., Zanca, A., Papini, M., Russo, A., Simonetti, O., Borghi, A., Corazza, M., Piaserico, S., Feliciani, C., Calzavara-Pinton, P., Amendolagine, G., Arisi, M., Babino, G., Bardazzi, F., Belloni Fortina, A., Caccavale, S., Campanati, A., Campione, E., Caposiena, C. D., Carugno, A., Coati, I., Cinotti, E., D'Antuono, A., Dattola, A., Dika, E., Fai, D., Fusano, M., Galluzzo, M., Ganzetti, G., Gisondi, P., Hansel, K., Lora, V., Maione, V., Mandel, V. D., Menni, S., Negosanti, M., Neri, I., Offidani, A., Parodi, A., Patrizi, A., Peserico, A., Rossi, M., Rivetti, N., Saccani, E., Stan, T. R., Stingeni, L., Talamonti, M., Vascellaro, A., Vezzoli, P., Virgili, A., Zanca, A., Papini, M, Russo, A, Simonetti, O, Borghi, A, Corazza, M, Piaserico, S, Feliciani, C, Calzavara-Pinton, P, Amendolagine, G, Arisi, M, Babino, G, Bardazzi, F, Belloni Fortina, A, Cac-Cavale, S, Campanati, A, Campione, E, Caposiena, C, Carugno, A, Coati, I, Cinotti, E, D'Antuono, A, Dattola, A, Dika, E, Fai, D, Fusano, M, Galluzzo, M, Ganzetti, G, Gisondi, P, Hansel, K, Lora, V, Maione, V, Mandel, V, Menni, S, Negosanti, M, Neri, I, Offidani, A, Parodi, A, Patrizi, A, Peserico, A, Rossi, M, Rivetti, N, Saccani, E, Stan, T, Stingeni, L, Talamonti, M, Vascellaro, A, Vezzoli, P, Virgili, A, Zanca, A, Papini M., Russo A., Simonetti O., Borghi A., Corazza M., Piaserico S., Feliciani C., Calzavara-Pinton P., Amendolagine G., Arisi M., Babino G., Bardazzi F., Belloni Fortina A., Cac-Cavale S., Campanati A., Campione E., Caposiena C.D., Carugno A., Coati I., Cinotti E., D'Antuono A., Dattola A., Dika E., Fai D., Fusano M., Galluzzo M., Ganzetti G., Gisondi P., Hansel K., Lora V., Maione V., Mandel V.D., Menni S., Negosanti M., Neri I., Offidani A., Parodi A., Patrizi A., Peserico A., Rossi M., Rivetti N., Saccani E., Stan T.R., Stingeni L., Talamonti M., Vascellaro A., Vezzoli P., Virgili A., and Zanca A. more...
- Subjects
Male ,medicine.medical_specialty ,Calcineurin Inhibitors ,Socio-culturale ,Disease ,Dermatology ,Lichen sclerosus ,Guideline ,Settore MED/35 ,Lichen sclerosus et atrophicu ,medicine ,Dysuria ,Humans ,Sex organ ,Drug therapy ,Lichen sclerosus et atrophicus ,Operative surgical procedures ,Rare diseases ,Vulvar lichen sclerosus ,Female ,Italy ,Mometasone Furoate ,Lichen Sclerosus et Atrophicus ,Calcineurin Inhibitor ,business.industry ,Mucous membrane ,Evidence-based medicine ,medicine.disease ,Infectious Diseases ,medicine.anatomical_structure ,Sexual dysfunction ,Operative surgical procedure ,Vulvar lichen sclerosu ,medicine.symptom ,business ,Rare disease ,Human - Abstract
Lichen sclerosus (LS) is a disabling chronic inflammatory disease of skin and genital mucous membrane causing itch, pain, dysuria and restriction of micturition, and significant sexual dysfunction and dyspareunia both in women and men. If left untreated, LS is associated with a high degree of sclerosis and scarring, as well as with an elevated risk of cancer in the genital area. Although a central role of autoimmunity is suggested, the pathogenesis of LS is still not clearly understood and the disease remains difficult to treat. The goals of treatment of LS are to alleviate symptoms and discomfort, prevent anatomical changes and prevent malignant transformation. This guideline has been developed by an Italian group of experts. It summarizes evidence-based and expert- based recommendations. The highest level of evidence favors the use of topical high potency corticosteroids; second- and third-line treatments include topical calcineurin inhibitors and topical retinoids, respectively. Surgical treatment has become the treatment of choice in male genital LS with persistent phimosis not responsive to medical treatment. The aim of this paper is to offer evidence-based and easily applicable recommendations for the management of LS. more...
- Published
- 2021
17. An under‐recognized, life‐threatening complication of atopic dermatitis
- Author
-
Pagliarello, C., Scrivani, S., Fabrizi, G., Feliciani, C., and Di Nuzzo, S.
- Published
- 2017
- Full Text
- View/download PDF
18. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
- Author
-
Borradori, L., primary, Van Beek, N., additional, Feliciani, C., additional, Tedbirt, B., additional, Antiga, E., additional, Bergman, R., additional, Böckle, B. C., additional, Caproni, M., additional, Caux, F., additional, Chandran, N.S., additional, Cianchini, G., additional, Daneshpazhooh, M., additional, De, D., additional, Didona, D., additional, Di Zenzo, G. M., additional, Dmochowski, M., additional, Drenovska, K., additional, Ehrchen, J., additional, Goebeler, M., additional, Groves, R., additional, Günther, C., additional, Horvath, B., additional, Hertl, M., additional, Hofmann, S., additional, Ioannides, D., additional, Itzlinger‐Monshi, B., additional, Jedličková, J., additional, Kowalewski, C., additional, Kridin, K., additional, Lim, Y. L., additional, Marinovic, B., additional, Marzano, A. V., additional, Mascaro, J.‐M., additional, Meijer, J.M., additional, Murrell, D., additional, Patsatsi, K., additional, Pincelli, C., additional, Prost, C., additional, Rappersberger, K., additional, Sárdy, M., additional, Setterfield, J., additional, Shahid, M., additional, Sprecher, E., additional, Tasanen, K., additional, Uzun, S., additional, Vassileva, S., additional, Vestergaard, K., additional, Vorobyev, A., additional, Vujic, I., additional, Wang, G., additional, Wozniak, K., additional, Yayli, S., additional, Zambruno, G., additional, Zillikens, D., additional, Schmidt, E., additional, and Joly, P., additional more...
- Published
- 2022
- Full Text
- View/download PDF
19. Development and Embryology of Oral Mucosa and Structures: Developmental Disturbances
- Author
-
Feliciani, C., Jordan, R., Lotti, Torello M., editor, Parish, Lawrence Charles, editor, and Rogers, Roy Steele, III, editor
- Published
- 1999
- Full Text
- View/download PDF
20. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
- Author
-
Yaylı, Savaş (ORCID 0000-0001-9402-940X & YÖK ID 151352), Borradori, L.; Van Beek, N.; Feliciani, C.; Tedbirt, B.; Antiga, E.; Bergman, R.; Boeckle, B. C.; Caproni, M.; Caux, F.; Chandran, N. S.; Cianchini, G.; Daneshpazhooh, M.; De, D.; Didona, D.; Di Zenzo, G. M.; Dmochowski, M.; Drenovska, K.; Ehrchen, J.; Goebeler, M.; Groves, R.; Guenther, C.; Horvath, B.; Hertl, M.; Hofmann, S.; Ioannides, D.; Itzlinger-Monshi, B.; Jedlickova, J.; Kowalewski, C.; Kridin, K.; Lim, Y. L.; Marinovic, B.; Marzano, A.; Mascaro, J. -M.; Meijer, J. M.; Murrell, D.; Patsatsi, K.; Pincelli, C.; Prost, C.; Rappersberger, K.; Sardy, M.; Setterfield, J.; Shahid, M.; Sprecher, E.; Tasanen, K.; Uzun, S.; Vassileva, S.; Vestergaard, K.; Vorobyev, A.; Vujic, I.; Wang, G.; Wozniak, K.; Zambruno, G.; Zillikens, D.; Schmidt, E.; Joly, P., School of Medicine, Yaylı, Savaş (ORCID 0000-0001-9402-940X & YÖK ID 151352), Borradori, L.; Van Beek, N.; Feliciani, C.; Tedbirt, B.; Antiga, E.; Bergman, R.; Boeckle, B. C.; Caproni, M.; Caux, F.; Chandran, N. S.; Cianchini, G.; Daneshpazhooh, M.; De, D.; Didona, D.; Di Zenzo, G. M.; Dmochowski, M.; Drenovska, K.; Ehrchen, J.; Goebeler, M.; Groves, R.; Guenther, C.; Horvath, B.; Hertl, M.; Hofmann, S.; Ioannides, D.; Itzlinger-Monshi, B.; Jedlickova, J.; Kowalewski, C.; Kridin, K.; Lim, Y. L.; Marinovic, B.; Marzano, A.; Mascaro, J. -M.; Meijer, J. M.; Murrell, D.; Patsatsi, K.; Pincelli, C.; Prost, C.; Rappersberger, K.; Sardy, M.; Setterfield, J.; Shahid, M.; Sprecher, E.; Tasanen, K.; Uzun, S.; Vassileva, S.; Vestergaard, K.; Vorobyev, A.; Vujic, I.; Wang, G.; Wozniak, K.; Zambruno, G.; Zillikens, D.; Schmidt, E.; Joly, P., and School of Medicine more...
- Abstract
Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. Objectives and methodology: the Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. Results: treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. Conclusions: the guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice., The guideline update was partly supported by the European Academy of Dermatology and Venereology (EADV) and the European Network for Rare Skin Disorders (ERN). more...
- Published
- 2022
21. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience
- Author
-
Stingeni, L, Bianchi, L, Antonelli, E, Caroppo, E S, Ferrucci, S M, Ortoncelli, M, Fabbrocini, G, Nettis, E, Schena, D, Napolitano, M, Gola, M, Bonzano, L, Rossi, M, Belloni Fortina, A, Balato, A, Peris, Ketty, Foti, C, Guarneri, F, Romanelli, M, Patruno, C, Savoia, P, Fargnoli, M C, Russo, F, Errichetti, E, Bianchelli, T, Pellacani, G, Feliciani, C, Offidani, A, Corazza, M, Micali, G, Milanesi, N, Malara, G, Chiricozzi, Andrea, Tramontana, M, Hansel, K, Peris, K (ORCID:0000-0002-5237-0463), Chiricozzi, A (ORCID:0000-0002-6739-0387), Stingeni, L, Bianchi, L, Antonelli, E, Caroppo, E S, Ferrucci, S M, Ortoncelli, M, Fabbrocini, G, Nettis, E, Schena, D, Napolitano, M, Gola, M, Bonzano, L, Rossi, M, Belloni Fortina, A, Balato, A, Peris, Ketty, Foti, C, Guarneri, F, Romanelli, M, Patruno, C, Savoia, P, Fargnoli, M C, Russo, F, Errichetti, E, Bianchelli, T, Pellacani, G, Feliciani, C, Offidani, A, Corazza, M, Micali, G, Milanesi, N, Malara, G, Chiricozzi, Andrea, Tramontana, M, Hansel, K, Peris, K (ORCID:0000-0002-5237-0463), and Chiricozzi, A (ORCID:0000-0002-6739-0387) more...
- Abstract
Background Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from >= 12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined. Methods Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. Results One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. Conclusions Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era. more...
- Published
- 2022
22. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis
- Author
-
Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Conti, A., Corazza, M., Costanzo, A., Dapavo, P., De Simone, Clara, Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, Ketty, Calzavara-Pinton, P., Chiricozzi A. (ORCID:0000-0002-6739-0387), DE Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Conti, A., Corazza, M., Costanzo, A., Dapavo, P., De Simone, Clara, Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, Ketty, Calzavara-Pinton, P., Chiricozzi A. (ORCID:0000-0002-6739-0387), DE Simone C. (ORCID:0000-0002-0898-0045), and Peris K. (ORCID:0000-0002-5237-0463) more...
- Abstract
SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by moderate to severe plaque psoriasis. The content of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline, suggestions for disease severity grading and treatment goals. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs including acitretin, cyclosporine, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. Moreover, the guideline provides guidance for specific clinical situations such as patient with concomitant psoriatic arthritis, inflammatory bowel disease, a history of malignancies, a history of depression, diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or those with childbearing potential. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided. more...
- Published
- 2022
23. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy
- Author
-
Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., Zangrilli A., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., and Zangrilli A. more...
- Published
- 2020
24. Calibration and validation of a simulation model for predicting pedestrian fatalities at unsignalized crosswalks by means of statistical traffic data
- Author
-
Feliciani, C, Gorrini, A, Crociani, L, Vizzari, G, Nishinari, K, Bandini, S, Feliciani C., Gorrini A., Crociani L., Vizzari G., Nishinari K., Bandini S., Feliciani, C, Gorrini, A, Crociani, L, Vizzari, G, Nishinari, K, Bandini, S, Feliciani C., Gorrini A., Crociani L., Vizzari G., Nishinari K., and Bandini S. more...
- Abstract
This work presents a simulation model for unsignalized crosswalks which takes into account collisions between vehicles and pedestrians, thus allowing to assess the estimated yearly pedestrian fatality. In particular, we focus on a method to calibrate such a model combining measurable crosswalk characteristics, such as maximum speed limit or drivers' compliance, with statistical data for past accidents obtained from local municipality. In order to perform simulations under realistic conditions, we constructed a one-week scenario where pedestrian and vehicle traffic vary using specific patterns each hour of the week. The constructed traffic profile is based on openly available data and the suitability for the scenario considered (a crosswalk in Milan, Italy) is investigated showing that cultural/lifestyle elements determine the variation of weekly traffic. Simulations using the constructed one-week scenario were used to obtain the only non-measurable parameter which account for pedestrians' and drivers' distraction. In addition, we also focused on the presence of elderly pedestrians which have different physiological characteristics compared to adults or children and are becoming an important part of the population in several countries around the globe. The simulation model presented here and the method suggested for calibration may be employed in different contexts, thus allowing to build an important tool to be used not only for transportation efficiency/optimization but also for safety analysis. more...
- Published
- 2020
25. The effect of COVID-19 emergency in the management of melanoma in Italy
- Author
-
Anichini, A., Asero, S., Bersanelli, M., Caraco, C., De Giorgi, V., Di Giacomo, A. M., Feliciani, C., Ferraresi, V., Ghiorzo, P., Grimaldi, A. M., Guida, M., Mandala, M., Massi, D., Mocellin, S., Palmieri, G., Patuzzo, R., Pizzichetta, M. A., Ricci, R., Rossi, G., Quaglino, P., Queirolo, P., Senetta, R., Stanganelli, I., Tucci, M., Anichini, A., Asero, S., Bersanelli, M., Caraco, C., De Giorgi, V., Di Giacomo, A. M., Feliciani, C., Ferraresi, V., Ghiorzo, P., Grimaldi, A. M., Guida, M., Mandala, M., Massi, D., Mocellin, S., Palmieri, G., Patuzzo, R., Pizzichetta, M. A., Ricci, R., Rossi, G., Quaglino, P., Queirolo, P., Senetta, R., Stanganelli, I., and Tucci, M. more...
- Subjects
medicine.medical_specialty ,Telemedicine ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Melanoma ,Sentinel lymph node ,COVID-19 ,Italy ,management ,Dermatology ,lcsh:RL1-803 ,medicine.disease ,Article ,Management ,Health services ,Pandemic ,medicine ,lcsh:Dermatology ,Skin melanoma ,Intensive care medicine ,business ,Melanoma diagnosis - Abstract
The COVID-19 pandemic has severely hampered the functioning of any health system, absorbing a considerable amount of resources and with the threat of widespread infection in the health services. The present survey has been carried out in Italy to evaluate if and how COVID-19 also affected skin melanoma management. We enrolled 13 Italian centres highly qualified in the diagnosis and care of skin melanoma. We compared a set of information evaluating the amount of activity for melanoma performed during February-April 2020 with the same quarter in 2019. The number of new melanoma diagnosis, biopsies, wide local excisions, overall pathology reports decreased. However, the most severe cases seem promptly managed with sentinel lymph node biopsies, new systemic treatments (north) and the total number of (advanced) treated patients (centre-south). The COVID-19 experience has underlined the need to exploit the help which may come from telemedicine. more...
- Published
- 2021
26. Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis. The LION real-life multicenter prospective observational cohort study
- Author
-
Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., Pigatto, P., Cruciani, G., De Simone, C., Caldarola, G., Grimaldi, M., Anedda, J., Bernardini, N., Marchesiello, A., Franchi, C., Dattola, A., Botti, E., Zedde, P., Cammarata, E., Radi, G., Rosi, E., De Rosa, A., Esposito, M., Marietti, R., Lupi, F., Grazzini, M., Domenico, D. M., Brusasco, M., Gai, F., Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., and on behalf of the LION study group—Italian Participating, Centers more...
- Subjects
Adult ,Male ,medicine.medical_specialty ,Dermatologic Agent ,psoriasis, therapy-topical ,Betamethasone dipropionate ,Dermatology ,Betamethasone ,NO ,chemistry.chemical_compound ,Patient satisfaction ,Calcitriol ,Psoriasis ,Internal medicine ,Drug Combination ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Calcipotriol ,psoriasi ,therapy-topical ,business.industry ,psoriasis ,General Medicine ,Middle Aged ,medicine.disease ,Prospective Studie ,Drug Combinations ,Treatment Outcome ,chemistry ,Patient Satisfaction ,Cohort ,Observational study ,Dermatologic Agents ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,business ,Cohort study ,medicine.drug ,Human - Abstract
Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. This study assessed patient's satisfaction with Cal/BD foam in a real-life Italian dermatological clinical practice. A multicenter, 4-week observational prospective cohort study enrolled, in 17 Italian dermatology clinics, adult patients with plaque psoriasis on the body and/or scalp. Treatment satisfaction was assessed by 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), preference over previous treatments by Patient Preference Questionnaire (PPQ), and change in disease state by Psoriasis Area Severity Index (PASI). Overall 256 patients were eligible, with a mean (SD) age of 55.6 (15.4) years, 59.4% were males. Psoriasis severity was mild in 52.0% of patients, moderate in 43.3%, and severe in 4.7%. Scalp involvement was present in 36.7% of patients. Previous antipsoriatic treatments had been received by 80.5% of patients. TSQM-9 median (25th-75th percentile) scores were 83.3 (66.7-88.9) for effectiveness, 77.8 (66.7-88.9) for convenience, and 78.6 (64.3-92.9) for global satisfaction. Mean (SD) PASI value decreased from 7.3 (4.8) to 2.1 (2.7) after 4 weeks. More than 90% of patients previously treated for psoriasis evaluated the Cal/BD foam more effective, easier to use and better tolerated compared to previous topical treatments at PPQ. This observational study provides real-life evidence of a high level of satisfaction with effectiveness and convenience of the Cal/BD foam in a cohort of plaque psoriasis patients, with an objective improvement in PASI. more...
- Published
- 2021
27. First report of hereditary Christ–Siemens–Touraine syndrome and non-segmental vitiligo association in a young adult: contraindication for vitiligo treatment
- Author
-
Garcovich, S., Gnarra, M., Murabit, A., Arena, V., Sani, I., and Feliciani, C.
- Published
- 2016
- Full Text
- View/download PDF
28. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology
- Author
-
Feliciani, C., Joly, P., Jonkman, M. F., Zambruno, G., Zillikens, D., Ioannides, D., Kowalewski, C., Jedlickova, H., Kárpáti, S., Marinovic, B., Mimouni, D., Uzun, S., Yayli, S., Hertl, M., and Borradori, L. more...
- Published
- 2015
- Full Text
- View/download PDF
29. Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)
- Author
-
Hertl, M., Jedlickova, H., Karpati, S., Marinovic, B., Uzun, S., Yayli, S., Mimouni, D., Borradori, L., Feliciani, C., Ioannides, D., Joly, P., Kowalewski, C., Zambruno, G., Zillikens, D., and Jonkman, M. F. more...
- Published
- 2015
- Full Text
- View/download PDF
30. Italian guidelines in diagnosis and treatment of alopecia areata
- Author
-
Rossi, A, Muscianese, M, Piraccini, B, Starace, M, Carlesimo, M, Mandel, V, Alessandrini, A, Calvieri, S, Caro, G, D'Arino, A, Federico, A, Magri, F, Pigliacelli, F, Amendolagine, G, Annunziata, M, Arisi, M, Astorino, S, Babino, G, Bardazzi, F, Barruscotti, S, Belloni Fortina, A, Borghi, A, Bruni, F, Caccavale, S, Calzavara-Pinton, P, Cameli, N, Cardone, M, Carugno, A, Coppola, R, Dattola, A, De Felici Del Giudice, M, Di Cesare, A, Dika, E, Dinunno, D, D'Ovidio, R, Fabbrocini, G, Feliciani, C, Fulgione, E, Galluzzo, M, Garcovich, S, Garelli, V, Guerriero, C, Hansel, K, La Placa, M, Lacarrubba, F, Lora, V, Marinello, E, Megna, M, Micali, G, Misciali, C, Monari, P, Monfrecola, G, Neri, I, Offidani, A, Orlando, G, Papini, M, Patrizi, A, Piaserico, S, Rivetti, N, Simonetti, O, Stan, T, Stingeni, L, Talamonti, M, Tassone, F, Villa, L, Vincenzi, C, Fortuna, M, Rossi A., Muscianese M., Piraccini B. M., Starace M., Carlesimo M., Mandel V. D., Alessandrini A., Calvieri S., Caro G., D'Arino A., Federico A., Magri F., Pigliacelli F., Amendolagine G., Annunziata M. C., Arisi M. C., Astorino S., Babino G., Bardazzi F., Barruscotti S., Belloni Fortina A., Borghi A., Bruni F., Caccavale S., Calzavara-Pinton P., Cameli N., Cardone M., Carugno A., Coppola R., Dattola A., De Felici Del Giudice M. B., Di Cesare A., Dika E., Dinunno D., D'Ovidio R., Fabbrocini G., Feliciani C., Fulgione E., Galluzzo M., Garcovich S., Garelli V., Guerriero C., Hansel K., La Placa M., Lacarrubba F., Lora V., Marinello E., Megna M., Micali G., Misciali C., Monari P., Monfrecola G., Neri I., Offidani A., Orlando G., Papini M., Patrizi A., Piaserico S., Rivetti N., Simonetti O., Stan T. R., Stingeni L., Talamonti M., Tassone F., Villa L., Vincenzi C., Fortuna M. C., Rossi, A, Muscianese, M, Piraccini, B, Starace, M, Carlesimo, M, Mandel, V, Alessandrini, A, Calvieri, S, Caro, G, D'Arino, A, Federico, A, Magri, F, Pigliacelli, F, Amendolagine, G, Annunziata, M, Arisi, M, Astorino, S, Babino, G, Bardazzi, F, Barruscotti, S, Belloni Fortina, A, Borghi, A, Bruni, F, Caccavale, S, Calzavara-Pinton, P, Cameli, N, Cardone, M, Carugno, A, Coppola, R, Dattola, A, De Felici Del Giudice, M, Di Cesare, A, Dika, E, Dinunno, D, D'Ovidio, R, Fabbrocini, G, Feliciani, C, Fulgione, E, Galluzzo, M, Garcovich, S, Garelli, V, Guerriero, C, Hansel, K, La Placa, M, Lacarrubba, F, Lora, V, Marinello, E, Megna, M, Micali, G, Misciali, C, Monari, P, Monfrecola, G, Neri, I, Offidani, A, Orlando, G, Papini, M, Patrizi, A, Piaserico, S, Rivetti, N, Simonetti, O, Stan, T, Stingeni, L, Talamonti, M, Tassone, F, Villa, L, Vincenzi, C, Fortuna, M, Rossi A., Muscianese M., Piraccini B. M., Starace M., Carlesimo M., Mandel V. D., Alessandrini A., Calvieri S., Caro G., D'Arino A., Federico A., Magri F., Pigliacelli F., Amendolagine G., Annunziata M. C., Arisi M. C., Astorino S., Babino G., Bardazzi F., Barruscotti S., Belloni Fortina A., Borghi A., Bruni F., Caccavale S., Calzavara-Pinton P., Cameli N., Cardone M., Carugno A., Coppola R., Dattola A., De Felici Del Giudice M. B., Di Cesare A., Dika E., Dinunno D., D'Ovidio R., Fabbrocini G., Feliciani C., Fulgione E., Galluzzo M., Garcovich S., Garelli V., Guerriero C., Hansel K., La Placa M., Lacarrubba F., Lora V., Marinello E., Megna M., Micali G., Misciali C., Monari P., Monfrecola G., Neri I., Offidani A., Orlando G., Papini M., Patrizi A., Piaserico S., Rivetti N., Simonetti O., Stan T. R., Stingeni L., Talamonti M., Tassone F., Villa L., Vincenzi C., and Fortuna M. C. more...
- Abstract
Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current available treatments have variable efficacy. Nowadays, there is relatively little evidence on treatment of AA from well-designed clinical trials. Moreover, none of the treatments or devices commonly used to treat AA are specifically approved by the Food and Drug Administration. The Italian Study Group for Cutaneous Annexial Disease of the Italian Society of dermatology proposes these Italian guidelines for diagnosis and treatment of Alopecia Areata deeming useful for the daily management of the disease. This article summarizes evidence-based treatment associated with expert-based recommendations. more...
- Published
- 2019
31. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I
- Author
-
Rashid, H., primary, Lamberts, A., additional, Borradori, L., additional, Alberti‐Violetti, S., additional, Barry, R.J., additional, Caproni, M., additional, Carey, B., additional, Carrozzo, M., additional, Caux, F., additional, Cianchini, G., additional, Corrà, A., additional, Diercks, G.F.H., additional, Dikkers, F.G., additional, Di Zenzo, G., additional, Feliciani, C., additional, Geerling, G., additional, Genovese, G., additional, Hertl, M., additional, Joly, P., additional, Marzano, A.V., additional, Meijer, J.M., additional, Mercadante, V., additional, Murrell, D.F., additional, Ormond, M., additional, Pas, H.H., additional, Patsatsi, A., additional, Prost, C., additional, Rauz, S., additional, van Rhijn, B.D., additional, Roth, M., additional, Schmidt, E., additional, Setterfield, J., additional, Zambruno, G., additional, Zillikens, D., additional, and Horváth, B., additional more...
- Published
- 2021
- Full Text
- View/download PDF
32. S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)
- Author
-
Görög, A., primary, Antiga, E., additional, Caproni, M., additional, Cianchini, G., additional, De, D., additional, Dmochowski, M., additional, Dolinsek, J., additional, Drenovska, K., additional, Feliciani, C., additional, Hervonen, K., additional, Lakos Jukic, I., additional, Kinyó, Á., additional, Koltai, T., additional, Korponay‐Szabó, I., additional, Marzano, A.V., additional, Patsatsi, A., additional, Rose, C., additional, Salmi, T., additional, Schmidt, E., additional, Setterfield, J., additional, Shahid, M., additional, Sitaru, C., additional, Uzun, S., additional, Valitutti, F., additional, Vassileva, S., additional, Yayli, S., additional, and Sárdy, M., additional more...
- Published
- 2021
- Full Text
- View/download PDF
33. Mutation identification of Fabry disease in families with other lysosomal storage disorders
- Author
-
Zampetti, A, Fania, L, Antuzzi, D, Giurdanella, F, Gnarra, M, Bertola, F, Lualdi, S, Filocamo, M, Morrone, A, and Feliciani, C
- Published
- 2013
- Full Text
- View/download PDF
34. Angiokeratoma: decision-making aid for the diagnosis of Fabry disease
- Author
-
Zampetti, A., Orteu, C. H., Antuzzi, D., Bongiorno, M. R., Manco, S., Gnarra, M., Morrone, A., Cardinali, G., Kovacs, D., Aspite, N., Linder, D., Parini, R., and Feliciani, C.
- Published
- 2012
- Full Text
- View/download PDF
35. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene
- Author
-
Ferri, L, Guido, C, la Marca, G, Malvagia, S, Cavicchi, C, Fiumara, A, Barone, R, Parini, R, Antuzzi, D, Feliciani, C, Zampetti, A, Manna, R, Giglio, S, Della Valle, C M, Wu, X, Valenzano, K J, Benjamin, E R, Donati, M A, Guerrini, R, Genuardi, M, and Morrone, A more...
- Published
- 2012
- Full Text
- View/download PDF
36. A case of acquired disseminated elastosis perforans serpiginosa in a patient with HIV, hepatitis B and hepatitis C successfully treated with narrowband ultraviolet B therapy
- Author
-
Di Nuzzo, S., primary, Bertolani, M., additional, Casanova, D., additional, Manuguerra, R, additional, de Felici del Giudice, M. B., additional, and Feliciani, C., additional
- Published
- 2020
- Full Text
- View/download PDF
37. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
- Author
-
Joly, P., primary, Horvath, B., additional, Patsatsi, Α, additional, Uzun, S., additional, Bech, R., additional, Beissert, S., additional, Bergman, R., additional, Bernard, P., additional, Borradori, L., additional, Caproni, M., additional, Caux, F., additional, Cianchini, G., additional, Daneshpazhooh, M., additional, De, D, additional, Dmochowski, M., additional, Drenovska, K., additional, Ehrchen, J., additional, Feliciani, C., additional, Goebeler, M., additional, Groves, R., additional, Guenther, C., additional, Hofmann, S., additional, Ioannides, D., additional, Kowalewski, C., additional, Ludwig, R., additional, Lim, Y.L., additional, Marinovic, B., additional, Marzano, A.V., additional, Mascaró, J.M., additional, Mimouni, D., additional, Murrell, D.F., additional, Pincelli, C., additional, Squarcioni, C.P., additional, Sárdy, M., additional, Setterfield, J., additional, Sprecher, E., additional, Vassileva, S., additional, Wozniak, K., additional, Yayli, S., additional, Zambruno, G., additional, Zillikens, D., additional, Hertl, M., additional, and Schmidt, E., additional more...
- Published
- 2020
- Full Text
- View/download PDF
38. Fabry disease: a review of current management strategies
- Author
-
Mehta, A., Beck, M., Eyskens, F., Feliciani, C., Kantola, I., Ramaswami, U., Rolfs, A., Rivera, A., Waldek, S., and Germain, D.P.
- Published
- 2010
- Full Text
- View/download PDF
39. Monocyte Chemotactic Protein-1 Gene Expression and Translation in Formed Granulomatous Calcified Tissue In Vivo
- Author
-
Conti, P., Feliciani, C., Barbacane, R. C., Frydas, S., Placido, F. C., Cataldo, I., and Reale, M.
- Published
- 1999
- Full Text
- View/download PDF
40. Adult self-healing papular mucinosis on genital skin
- Author
-
Feliciani, C., Pennacchia, I., and Massi, G.
- Published
- 2009
- Full Text
- View/download PDF
41. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses
- Author
-
Feliciani, C., Caldarola, G., Kneisel, A., Podstawa, E., Pfütze, M., Pfützner, W., and Hertl, M.
- Published
- 2009
- Full Text
- View/download PDF
42. Systematic experimental investigation of the obstacle effect during non-competitive and extremely competitive evacuations
- Author
-
Feliciani, C. (Claudio), Zuriguel-Ballaz, I. (Iker), Montero, Á. (Ángel), Maza-Ozcoidi, D. (Diego), and Nishinari, K. (Katsuhiro)
- Subjects
Física - Abstract
Although some experimental evidence showed that an obstacle placed in front of a door allows making people's evacuations faster, the efficacy of such a solution has been debated for over 15 years. Researchers are split between those who found the obstacle beneficial and those who could not find a significant difference without it. One of the reasons for the several conclusions lies in the variety of the experiments performed so far, both in terms of competitiveness among participants, geometrical configuration and number of participants. In this work, two unique datasets relative to evacuations with/without obstacle and comprising low and high competitiveness are analyzed using state-of-the-art definitions for crowd dynamics. In particular, the so-called congestion level is employed to measure the smoothness of collective motion. Results for extreme conditions show that, on the overall, the obstacle does not reduce density and congestion level and it could rather slightly increase it. From this perspective, the obstacle was found simply shifting the dangerous spots from the area in front of the exit to the regions between the obstacle and the wall. On the other side, it was however confirmed, that the obstacle can stabilize longitudinal crowd waves, thus reducing the risk of trampling, which could be as important (in terms of safety) as improving the evacuation time. more...
- Published
- 2020
43. Exacerbation of pemphigus after influenza vaccination
- Author
-
De Simone, C., Caldarola, G., Dʼagostino, M., Zampetti, A., Amerio, P., and Feliciani, C.
- Published
- 2008
44. Circumscribed pityriasis rubra pilaris type IV
- Author
-
Caldarola, G., Zampetti, A., De Simone, C., Massi, G., Amerio, P., and Feliciani, C.
- Published
- 2007
45. Bullous Wells syndrome
- Author
-
Feliciani, C, Motta, A, Tortorella, R, De Benedetto, A, Amerio, P, and Tulli, A
- Published
- 2006
46. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B + C and 4
- Author
-
Amerio, P., Tracanna, M., De Remigis, P., Betterle, C., Vianale, L., Marra, M. E., Di Rollo, D., Capizzi, R., Feliciani, C., and Tulli, A.
- Published
- 2006
47. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy
- Author
-
Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), and De Simone C. (ORCID:0000-0002-0898-0045) more...
- Abstract
N/A
- Published
- 2020
48. Scrofuloderma induced by surgical drainage in a joint tuberculosis
- Author
-
Zampetti, A., Feliciani, C., Capizzi, R., Valenzano, F., Manco, S., and Amerio, P. L.
- Published
- 2005
49. International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg−1 per day starting dose of oral corticosteroids to treat bullous pemphigoid.
- Author
-
Hébert, V., Bastos, S., Drenovska, K., Meijer, J., Ingen‐Housz‐Oro, S., Bedane, C., Lunardon, L., Debarbieux, S., Jedlickova, H., Caux, F., Chaby, G., D'Incan, M., Feliciani, C., Boulard, C., Schumacher, N., Schmidt, E., Roussel, A., Richard, M.A., Gottlieb, J., and Ferranti, V. more...
- Subjects
BULLOUS pemphigoid ,KARNOFSKY Performance Status ,CORTICOSTEROIDS ,SCIENTIFIC observation ,OVERALL survival - Abstract
Summary: Background: European guidelines propose a 0·5 mg kg−1 per day dose of oral prednisone as initial treatment for bullous pemphigoid (BP). We assessed the safety and efficacy of this regimen depending on BP extent and general condition of the patients. Methods: In a prospective international study, we consecutively included all patients diagnosed with BP. Patients received a 0·5 mg kg−1 per day dose of prednisone, which was then gradually tapered 15 days after disease control, with the aim of stopping prednisone or maintaining minimal treatment (0·1 mg kg−1 per day) within 6 months after the start of treatment. The two coprimary endpoints were control of disease activity at day 21 and 1‐year overall survival. Disease severity was assessed according to the Bullous Pemphigoid Disease Area Index (BPDAI) score. Results: In total, 198 patients were included between 2015 and 2017. The final analysis comprised 190 patients with a mean age of 80·9 (SD 9·1) years. Control of disease activity was achieved at day 21 in 119 patients [62·6%, 95% confidence interval (CI) 55·3–69.5]; 18 of 24 patients (75%, 95% CI 53·3–90·2), 75 of 110 patients (68·8%, 95% CI 59·2–77·3) and 26 of 56 patients (46.4%, 95% CI 33·0–60·3) had mild, moderate and severe BP, respectively (P = 0·0218). A total of 30 patients died during the study. The overall Kaplan–Meier 1‐year survival was 82·6% (95% CI 76·3–87·4) corresponding to 90·9%, 83·0% and 80·0% rates in patients with mild, moderate and severe BP, respectively (P = 0·5). Thresholds of 49 points for BPDAI score and 70 points for Karnofsky score yielded maximal Youden index values with respect to disease control at day 21 and 1‐year survival, respectively. Conclusions: A 0·5 mg kg−1 per day dose of prednisone is a valuable therapeutic option in patients with mild or moderate BP whose general condition allows them to be autonomous. What is already known about this topic? Superpotent topical corticosteroids are the gold standard treatment for bullous pemphigoid (BP), whatever the severity.High doses of oral corticosteroids are effective but poorly tolerated in patients with BP.Medium doses of oral corticosteroids are effective in paucibullous BP, but their efficacy in severe forms has not yet been assessed. What does this study add? Medium doses of oral corticosteroids have poor efficacy in severe BP.A baseline Bullous Pemphigoid Disease Area Index score < 50 and a Karnofsky score ≥ 70 are predictors of treatment efficacy and low mortality, respectively. Linked Comment: H.Y. Lee. Br J Dermatol 2021; 185:1093–1094. [ABSTRACT FROM AUTHOR] more...
- Published
- 2021
- Full Text
- View/download PDF
50. Alcoholism as a trigger of multiple symmetric lipomatosis?
- Author
-
Morelli, F, Feliciani, C, De Benedetto, A, Toto, P, and Tulli, A
- Published
- 2003
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.